EGFR and HER2 Expression in Primary Ovarian High-Grade Serous Carcinoma and Their Prognostic Value
Farrag, M., Emarah, Z., Elrefaie, W., Farrag, N., Hafez, M., Abdelwahab, K. (2021). EGFR and HER2 Expression in Primary Ovarian High-Grade Serous Carcinoma and Their Prognostic Value. EKB Journal Management System, 17(1), 9-16. doi: 10.21608/resoncol.2020.43021.1115
Mayada S. Farrag; Ziad Emarah; Waleed Elrefaie; Nesrine S. Farrag; Mohamed T. Hafez; Khaled Abdelwahab. "EGFR and HER2 Expression in Primary Ovarian High-Grade Serous Carcinoma and Their Prognostic Value". EKB Journal Management System, 17, 1, 2021, 9-16. doi: 10.21608/resoncol.2020.43021.1115
Farrag, M., Emarah, Z., Elrefaie, W., Farrag, N., Hafez, M., Abdelwahab, K. (2021). 'EGFR and HER2 Expression in Primary Ovarian High-Grade Serous Carcinoma and Their Prognostic Value', EKB Journal Management System, 17(1), pp. 9-16. doi: 10.21608/resoncol.2020.43021.1115
Farrag, M., Emarah, Z., Elrefaie, W., Farrag, N., Hafez, M., Abdelwahab, K. EGFR and HER2 Expression in Primary Ovarian High-Grade Serous Carcinoma and Their Prognostic Value. EKB Journal Management System, 2021; 17(1): 9-16. doi: 10.21608/resoncol.2020.43021.1115

EGFR and HER2 Expression in Primary Ovarian High-Grade Serous Carcinoma and Their Prognostic Value

Research in Oncology
Article 2, Volume 17, Issue 1, June 2021, Page 9-16  XML PDF (523.83 K)
Document Type: Original Article
DOI: 10.21608/resoncol.2020.43021.1115
View on SCiNiTO View on SCiNiTO
Authors
Mayada S. Farrag email orcid 1; Ziad Emarah2; Waleed Elrefaie3; Nesrine S. Farrag4; Mohamed T. Hafez5; Khaled Abdelwahab5
1Department of Pathology, Faculty of Medicine, Port Said University, Port Said, Egypt
2Medical Oncology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
3Department of Obstetrics and Gynecology, Faculty of Medicine, Port Said University, Port Said, Egypt
4Department of Community Medicine and Public Health, Faculty of Medicine, Mansoura University, Mansoura, Egypt
5Department of Surgical Oncology, Mansoura Oncology Center, Mansoura University, Mansoura, Egypt
Abstract
Background: Human epidermal growth factors receptors such as EGFR and HER2 play an important role in tumorigenesis and are used as therapeutic targets. Their role in aggressive primary ovarian high-grade serous carcinoma (HGSC) is controversial.
Aim: To study the expression of EGFR and HER2 in ovarian HGSC, to correlate their expression with other clinicopathological parameters and to study their prognostic value.
Methods: Imunohistochemical staining of EGFR, HER2 and Ki-67 was done for 54 ovarian HGSC specimens. According to the used scoring methods, the expression of EGFR and HER2 was classified as high or low.
Results: High expression of EGFR and HER2 was found in a minority of specimens; 39% and 15%, respectively. None of the studied clinicopathological parameters correlated significantly with the expression of EGFR and HER2, except for the carcinoembryonic antigen level which correlated positively with HER2 expression. Disease-free survival of patients did not differ significantly according to the level of expression of EGFR and HER2 (p =0.684 and 0.186, respectively). Similarly, overall survival did not differ significantly (p =0.911 and 0.346, respectively).
Conclusion: The results of this study suggest that the prognostic value of EGFR and HER2 in ovarian HGSC is questionable.
 
Keywords
EGFR; HER2; High-grade; Ovarian; Serous Carcinoma
Statistics
Article View: 525
PDF Download: 3,248